You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Viralytics Ltd (VLA) is an Australian biotechnology company focusing on developing oncolytic virotherapy for the treatment of a range of cancers. VLA ’s principal asset is the intellectual property relating to CAVATAK, an Oncolytic Virus Technology, and its current product development and pipeline includes CAVATAK and EVATAK. VLA holds granted patents in all major markets including the USA and Europe.
Handing over, what if you need someone else to make decisions for you? There are times in your life when you can't fulfil your financial obligations personally.
The Age 25/05/2013 |
In the mid-1960s, when Australia's trade minister Sir John McEwen was urging Holden and Ford to seek export markets in Asia, the leader of one of Asia's poorest countries decided his country needed a car industry.
The Age 25/05/2013 |
Debts to tradespeople and suppliers by collapsed builder National Buildplan Group have blown out to $58 million but administrators say they are likely to recoup only cents in the dollar.
The Age 25/05/2013 |
There's a simple message in what appeared to be conflicting statements from the Federal Reserve, its chairman, Ben Bernanke, and an assortment of other Fed heavies this week about the timing of a move to re-tighten monetary policy.
The Age 25/05/2013 |
Investors are contemplating a future without support from one of the biggest drivers of the global economy in recent years - the US Federal Reserve.
Already a member? 
$ 0.285
